ArticleBMC anesthesiology2026
Residual gastric content after holding of glucagon-like peptide-1 receptor agonists before elective surgery: a cross-sectional study - the RESIDUAL study.
Article in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06500143 (The RESIDUAL Study), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The RESIDUAL Study : Residual Gastric Content After Holding of Glucagon-like Peptide-1 Receptor Agonists Before Elective Surgery: a Cross-sectional Study
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGlucagon-like peptide-1 receptor agonists (GLP-1 RA) are now increasingly used for glycemic control in type 2 diabetes mellitus as well as for weight loss. Their effect on gastric emptying may increase the risk of aspiration in the perioperative setting; unfortunately, the optimal schedule of perioperative holding of GLP-1 RA is unclear.
methodsWe conducted a cross-sectional prospective study at two university affiliated hospitals in Montreal, Canada, comparing the preoperative prevalence of increased residual gastric content (RGC) on gastric ultrasound (GUS) between two groups of fasted adults scheduled for elective surgery: (i) an exposure group of patients receiving a weekly injectable GLP-1 RA and discontinued for ≥ 7 days before surgery, regardless of indication; and (ii) a control group of patients not receiving any GLP-1 RA, preferentially with type 2 diabetes or with a body mass index ≥ 25 kg/m². The primary outcome was increased RGC, defined as the presence of solid content, thick liquid, or > 1.5 mL/kg of clear liquid. Confounding was addressed using overlap-weighting propensity-score adjustment.
results93 patients were included. The unadjusted prevalence of increased RGC was 24% (10/41) in the control group and 42% (22/52) in the exposure group. Solid content accounted for 80% (8/10) and 82% (18/22) of positive exams in the control group and the exposure group, respectively. In the unadjusted analysis, there was no statistically significant difference in increased RGC between groups (prevalence ratio, 1.73; 95% CI, 0.96 to 3.75). There was no statistically significant difference between groups after adjustment for confounding (adjusted prevalence ratio, 1.65; 95% CI, 0.7 to 3.7) with an absolute average treatment effect of 15.4% (95% CI, -10 to 35.6).
conclusionsThe prevalence of increased residual gastric content was 42% in patients who had discontinued weekly GLP-1 RA for at least 7 days, compared with 24% in non-exposed controls. Although this difference was not statistically significant, our study was underpowered. The findings therefore represent a clinically relevant but statistically inconclusive signal that the recommended 7-day discontinuation interval may not consistently restore an empty stomach in patients on weekly GLP-1 RA.
trial registrationThis study was registered on clinicaltrials.gov (July 8th, 2024, NCT06500143).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.